This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sulavik, M. C. Articles by Barg, N. L. Search for Related Content PubMed PubMed Citation Articles by Sulavik, M. C. Articles by Barg, N. L.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, December 1998, p. 3317-3319, Vol. 42, No. 12
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Examination of Methicillin-Resistant and Methicillin-Susceptible Staphylococcus aureus Mutants with Low-Level Fluoroquinolone Resistance

Mark C. Sulavik and Neil L. Barg^*

Department of Medicine, Division of Infectious Diseases, University of Michigan Medical School, and Department of Veterans Affairs Medical Center, Ann Arbor, Michigan

Received 12 January 1998/Returned for modification 25 February 1998/Accepted 17 September 1998

	ABSTRACT

Top Abstract Text References

For Staphylococcus aureus, stepwise mutations result in high-level quinolone resistance. Methicillin-resistant and -susceptible quinolone-resistant, first-step mutants generated in vitro were obtained and found to be no different than those recovered from murine abscesses. Approximately 10% of all first-step mutants were resistant to ethidium bromide, and selected strains had mutations that mapped to flqB. NorA-mediated resistance among first-step mutants may be more prevalent than previously reported.

	TEXT

Top Abstract Text References

Resistance to fluoroquinolones occurs in a stepwise fashion (24). The mutants initially obtained are resistant to low concentrations of quinolones (first-step mutants), and subsequent mutations lead to higher-level resistance. The most common mutation conferring low-level resistance occurs in the flqA locus (3, 4, 25). DNA topoisomerase IV, encoded at the flqA locus, is the primary target of fluoroquinolones (3, 4, 16, 26) for Staphylococcus aureus but not necessarily for other bacterial species. Some flqA mutants are also hypersusceptible to novobiocin (25) (Nov^hs), and mutations of selected strains map to grlB (6). Second-step mutations have been identified in gyrA. Mutations in gyrA, plus a mutation in topoisomerase IV (grlA/flqA) (3, 16, 26), confer high-level resistance to quinolone antibiotics. A mutation only in gyrA has no effect on susceptibility to quinolones (16, 26); thus, such mutations have not been found among first-step mutants (3, 4, 7, 8, 9, 19, 25). Low-level quinolone resistance due to increased expression of the NorA multidrug efflux pump are due to mutations in the flqB locus (17) and possibly other loci (10). However, it is unclear when, or at what stage in resistance, altered NorA expression occurs. Here we present data implicating a role for NorA in first-step quinolone resistance.

There are limited data regarding the effect of the passage of strains in vivo on the ability to detect first-step mutants from common staphylococcal infections such as those of the skin. In vivo passage without quinolone selection might result in positive or negative selection for different classes of fluoroquinolone-resistant mutants. In the present study, we found that passage in vivo did not alter the distribution of different classes of first-step mutants for both methicillin-resistant S. aureus (MRSA) and methicillin-susceptible S. aureus (MSSA) clinical strains.

Methods and reagents. Tetracycline and erythromycin were used at 10 and 5 µg/ml, respectively. Resistance to fusidic acid (Fus^r), ciprofloxacin (Cfx^r), or ethidium bromide (Ebr^r) was determined when growth was evident on brain heart infusion agar (BHA) containing fusidic acid (10 µg/ml), ciprofloxacin (1 µg/ml), or ethidium bromide (20 µg/ml).

Broth microdilution MIC determinations were done with cation-adjusted Mueller-Hinton broth (1). BHA-novobiocin gradient plate assays were performed according to the method of Szybalski (21). Strains were considered Nov^hs when the length of confluent growth across a gradient plate containing novobiocin (0 to 0.25 µg/ml) was <66% of that of the parental strain. Identification to the species level was performed and clonality of mutant colonies was confirmed with an Acustaph kit (Carr-Scarborough Microbiologicals, Inc., Decatur, Ga.) and by pulsed-field gel electrophoresis of SmaI-digested genomic DNA (22), respectively.

Three-day murine abscess formation was performed by the method of Bunce et al. (2) using an initial inoculum of 10⁷ CFU of S. aureus.

High-molecular-weight DNA was obtained and transformations were done as described previously (20), with genetic mapping strains (18).

Results. Using a modification of published methods (3, 8, 23, 25), we isolated quinolone-resistant mutants from broth cultures (in vitro mutants) and from murine abscesses (in vivo-passaged mutants). Consistent with previous reports (5, 12, 14), more quinolone-resistant mutants were recovered by using ciprofloxacin than by using either ofloxacin or levofloxacin. For in vitro mutants, 10⁸ CFU of 38 independent brain heart infusion broth cultures of the laboratory strain RN4220 (13) were inoculated onto BHA containing 1 µg of ciprofloxacin per ml (two times the MIC). A mean of 11 colonies/10⁸ CFU were obtained after 24 h of incubation at 37°C. Selection with ofloxacin at the same concentration (two times the MIC) yielded fivefold fewer mutants than those obtained by ciprofloxacin selection. Data similar to those above were obtained for MSSA (NB1720 and NB1722) and MRSA (NB1725 and NB1726) clinical strains. Except for a single mutant obtained from strain NB1726, no mutants were obtained with levofloxacin selection at two times the MIC (0.75 µg/ml).

Low-level-quinolone-resistant mutants were obtained from murine abscesses (in vivo-passaged mutants) infected with S. aureus RN4220 or MSSA or MRSA clinical strains at frequencies similar to those obtained for in vitro mutants (Table 1). It is possible that first-step mutants existed at the time of infection and persisted within the abscess because of the inoculum used to produce the abscess. It is also possible that some first-step mutants emerged during infection and were not differentially eliminated during growth.

View this table: [in this window] [in a new window]   TABLE 1.   Isolation of quinolone-resistant mutants derived from quinolone-susceptible strains present in murine abscesses

For all first-step mutants obtained, the mean MIC of ciprofloxacin increased approximately fourfold above the mean MIC for parental strains. For ofloxacin and levofloxacin, the increases were two- to threefold. Thus, compared to ciprofloxacin, the relative potency of levofloxacin and ofloxacin increased with single-step resistancea result consistent with those of Thomson et al. (23).

Next, the phenotypes of first-step mutants were characterized. Ebr^r is an indicator of increased norA expression (10), and Nov^hs is an indicator of mutant alleles of flqA (topoisomerase IV). Both phenotypes were found among the in vitro- and the in vivo-passaged mutants. In 38 independent experiments, RN4220 was inoculated onto solid media containing 1 µg of ciprofloxacin per ml, and one resistant mutant per experiment was selected. Of the 38 chosen, 10 were Nov^hs and 1 was Ebr^r. A different sampling procedure yielded a higher percentage of Ebr^r mutants. Instead of sampling one mutant from many in an individual experiment, all mutants obtained on a plate in each of six experiments were examined. When all first-step mutants were sampled in each experiment, a mean of 13% of mutants were Ebr^r. For in vivo-passaged mutants, of 54 obtained from 18 mouse abscesses infected with RN4220, 30 were Nov^hs while 8 (derived from 5 abscesses) were Ebr^r. Of 27 MSSA isolates (NB1721) obtained from 8 abscesses, 8 were Nov^hs while none were Ebr^r, and for 27 MRSA isolates (NB1725) derived from 10 abscesses, 6 were Nov^hs and 3 were Ebr^r. Interestingly, although first-step mutants were heterogeneous based on susceptibilities to Ebr, MICs of the three quinolones tested were equivalent for all Ebr^s and Ebr^r mutants. The data suggest that for first-step mutants, resistance may be mediated by mutations affecting either topoisomerase IV or NorA.

Quinolone resistance caused by increased expression of norA (16) is detected by cross-resistance to other NorA substrates, such as ethidium bromide and cetrimide (10). Resistance to these substrates is reduced by the NorA inhibitor, reserpine (11, 15). Among the quinolone-resistant strains in Table 2, only the Ebr^r strains showed fourfold increases in resistance to cetrimide. In our hands, reserpine did not differentiate quinolone-resistant strains that were Ebr^r from those that were Ebr^s, because it reduced resistance levels in all strains tested. For EbrR first-step mutants, the data support the argument for mediation of quinolone resistance by NorA.

View this table: [in this window] [in a new window]   TABLE 2.   Susceptibilities of parental and first-step mutant strains to selected NorA substrates

Mutations in the flqB locus, and possibly in other loci (10), result in the increased expression of norA (25), which confers ciprofloxacin, Ebr, and cetrimide resistance (11, 15). Selected Cfx^r Ebr^r VA476 and VA331 strains were found to have mutations that mapped by genetic transformation to the flqB locus (Table 3). The data suggest a gene order as follows: fus, 1108 locus, Cfx^r Ebr^r locus. The cotransformation frequencies and gene order are similar to those reported for 1108 and flqB (4%) by Ng et al. (17). Thus, the Cfx^r Ebr^r locus maps to a location similar to that for flqB. In addition, the absence of discordance between Cfx^r and Ebr^r phenotypes in genetic crosses suggests that the same locus is responsible for both phenotypes. Mutations in the grlA/flqA locus have been shown to confer resistance to ciprofloxacin (25). Here, mutations in our Cfx^r Ebr^s strains, VA3 and VA352, mapped to the flqA locus (Table 3). The ~50 and 11% cotransformation frequencies of (Tn917lac)2 and (Tn917lac)1 with the Cfx^r locus are consistent with the 43 and 10% cotransduction frequencies with flqA, respectively, identified by Trucksis et al. (25).

View this table: [in this window] [in a new window]   TABLE 3.   Linkage of Cfxr Ebrr S. aureus with (chr::Tn916)1108 and Cfxr S. aureus with (chr::Tn917lac)2 and (chr::Tn917lac)1

We conclude that first-step quinolone-resistant MRSA and MSSA strainswhether obtained in vitro or via in vivo passageharbor either mutations in topoisomerase IV or mutations that alter NorA multidrug efflux pump activity.

	ACKNOWLEDGMENTS

We thank David Hooper and Terri Kenney for their helpful comments.

This work was supported in part by a grant from the Robert Wood Johnson Pharmaceutical Research Institute.

	FOOTNOTES

^* Corresponding author. Present address: Internal Medicine Associates of Yakima, 316 Holton Ave., Yakima, WA 98902. Phone: (509) 575-7666. Fax: (509) 576-4370. E-mail: nbarg{at}umich.edu.

Present address: Genome Therapeutics Corporation, Waltham, MA 02453.

	REFERENCES

Top Abstract Text References

1.	Amsterdam, D. 1996. Susceptibility testing of antimicrobials in liquid media, p. 52-111. In V. Lorian (ed.), Antibiotics in laboratory medicine, 4th ed. Williams and Wilkins, Baltimore, Md.
2.	Bunce, C., L. Wheeler, G. Reed, J. Musser, and N. Barg. 1992. Murine model of cutaneous infection with gram-positive cocci. Infect. Immun. 60:2636-2640[Abstract/Free Full Text].
3.	Ferrero, L., B. Cameron, and J. Crouzet. 1995. Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus. Antimicrob. Agents Chemother. 39:1554-1558[Abstract].
4.	Ferrero, L., B. Cameron, B. Manse, D. Lagneaux, J. Crouzet, A. Famechon, and F. Blanche. 1994. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones. Mol. Microbiol. 13:641-653[Medline].
5.	Forstall, G. J., C. C. Knapp, and J. A. Washington. 1991. Activity of new quinolones against ciprofloxacin-resistant staphylococci. Antimicrob. Agents Chemother. 35:1679-1681[Abstract/Free Full Text].
6.	Fournier, B., and D. C. Hooper. 1998. Mutations in topoisomerase IV and DNA gyrase of Staphylococcus aureus: novel pleiotropic effects on quinolone and coumarin activity. Antimicrob. Agents Chemother. 42:121-128[Abstract/Free Full Text].
7.	Goswitz, J. J., K. E. Willard, C. E. Fashing, and L. R. Peterson. 1992. Detection of gryA gene mutations associated with ciprofloxacin resistance in methicillin-resistant Staphylococcus aureus: analysis by polymerase chain reaction and automated direct DNA sequencing. Antimicrob. Agents Chemother. 36:1166-1169[Abstract/Free Full Text].
8.	Hori, S., Y. Ohshita, Y. Utsui, and K. Hiramatsu. 1993. Sequential acquisition of norfloxacin and ofloxacin resistance by methicillin-resistant and -susceptible Staphylococcus aureus. Antimicrob. Agents Chemother. 37:2278-2284[Abstract/Free Full Text].
9.	Ito, H., H. Yoshida, M. Bogaki-Shonai, T. Niga, H. Hattori, and S. Nakamura. 1994. Quinolone resistance mutations in the DNA gyrase gyrA and gyrB genes of Staphylococcus aureus. Antimicrob. Agents Chemother. 38:2014-2023[Abstract/Free Full Text].
10.	Kaatz, G. W., and S. M. Seo. 1995. Inducible NorA-mediated multidrug resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 39:2650-2655[Abstract].
11.	Kaatz, G. W., S. M. Seo, and C. A. Ruble. 1993. Efflux-mediated fluoroquinolone resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 37:1086-1094[Abstract/Free Full Text].
12.	Kang, S. L., M. J. Rybak, B. J. McGrath, G. W. Kaatz, and S. M. Seo. 1994. Pharmacodynamics of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with rifampin, against methicillin-susceptible and -resistant Staphylococcus aureus in an in vitro infection model. Antimicrob. Agents Chemother. 38:2702-2709[Abstract/Free Full Text].
13.	Kreiswirth, B. N., S. Lofdahl, M. J. Betley, M. O'Reilly, P. M. Schlievert, M. Bergdoll, and R. P. Novick. 1983. The toxic shock syndrome exotoxin structural gene is not detectably transmitted by a prophage. Nature 305:709-712[Medline].
14.	Maple, P. A. C., J. M. T. Hamilton-Miller, and W. Brumfitt. 1991. Differing activities of quinolones against ciprofloxacin-susceptible and ciprofloxacin-resistant, methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 35:345-350[Abstract/Free Full Text].
15.	Neyfakh, A. A., C. M. Borsch, and G. W. Kaatz. 1993. Fluoroquinolone resistance protein NorA of Staphylococcus aureus is a multidrug efflux transporter. Antimicrob. Agents Chemother. 37:128-129[Abstract/Free Full Text].
16.	Ng, E. Y., M. Trucksis, and D. C. Hooper. 1996. Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus. Antimicrob. Agents Chemother. 40:1881-1888[Abstract].
17.	Ng, E. Y. W., M. Trucksis, and D. C. Hooper. 1994. Quinolone resistance mediated by norA: a physiologic characterization and relationship to flqB, a quinolone resistance locus on the Staphylococcus aureus chromosome. Antimicrob. Agents Chemother. 38:1345-1355[Abstract/Free Full Text].
18.	Pattee, P. A. 1990. Genetic and physical mapping of the chromosome of Staphylococcus aureus NCTC 8325. American Society for Microbiology, Washington, D.C.
19.	Sreedharan, S., M. Oram, B. Jensen, L. R. Peterson, and L. M. Fisher. 1990. DNA gyrase gyrA mutations in ciprofloxacin-resistant strains of Staphylococcus aureus: close similarity with quinolone resistance mutations in Escherichia coli. J. Bacteriol. 172:7260-7262[Abstract/Free Full Text].
20.	Stahl, M. L., and P. A. Pattee. 1983. Confirmation of protoplast fusion-derived linkages in Staphylococcus aureus by transformation with protoplast DNA. J. Bacteriol. 154:406-412[Abstract/Free Full Text].
21.	Szybalski, W. 1952. Microbial selection. I. Gradient plate technique for study of bacterial resistance. Science 116:46-48.
22.	Tenover, F. C., R. D. Arbeit, R. V. Goering, P. A. Mickelsen, B. E. Murray, D. H. Persing, and B. Swaminathan. 1995. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J. Clin. Microbiol. 33:2233-2239[Medline].
23.	Thomson, K. S., C. C. Sanders, and M. E. Hyden. 1991. In vitro studies with five quinolones: evidence for changes in relative potency as quinolone resistance rises. Antimicrob. Agents Chemother. 35:2329-2334[Abstract/Free Full Text].
24.	Trucksis, M., D. C. Hooper, and J. S. Wolfson. 1991. Emerging resistance to fluoroquinolones in staphylococci: an alert. Ann. Intern. Med. 114:424-426.
25.	Trucksis, M., J. S. Wolfson, and D. C. Hooper. 1991. A novel locus conferring fluoroquinolone resistance in Staphylococcus aureus. J. Bacteriol. 173:5854-5860[Abstract/Free Full Text].
26.	Yamagishi, J.-I., T. Kojima, Y. Oyamada, K. Fujimoto, H. Hattori, S. Nakamura, and M. Inoue. 1996. Alterations in the DNA topoisomerase IV grlA gene responsible for quinolone resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 40:1157-1163[Abstract].

This article has been cited by other articles:

• Gilbert, D. N., Kohlhepp, S. J., Slama, K. A., Grunkemeier, G., Lewis, G., Dworkin, R. J., Slaughter, S. E., Leggett, J. E. (2001). Phenotypic Resistance of Staphylococcus aureus, Selected Enterobacteriaceae, and Pseudomonas aeruginosa after Single and Multiple In Vitro Exposures to Ciprofloxacin, Levofloxacin, and Trovafloxacin. Antimicrob. Agents Chemother. 45: 883-892 [Abstract] [Full Text]  
• Markham, P. N., Westhaus, E., Klyachko, K., Johnson, M. E., Neyfakh, A. A. (1999). Multiple Novel Inhibitors of the NorA Multidrug Transporter of Staphylococcus aureus. Antimicrob. Agents Chemother. 43: 2404-2408 [Abstract] [Full Text]  

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sulavik, M. C. Articles by Barg, N. L. Search for Related Content PubMed PubMed Citation Articles by Sulavik, M. C. Articles by Barg, N. L.